Athersys Inc (ATHXQ)

[goupupup]

I'm thinking a short-term solution that Mitsubishi, which has demonstrated A LOT of interest in MS for ARDS in Japan, would LOVE to get more exposure in many other countries along with the Marketing rights etc. including being a shareholder along with Helios. They have done PLENTY of due diligence Regarding MS a Mitsubishi partnership would be HUGE which they are sold on the merits, and they would also venture further. With more trial result in store this is a SLAM DUNK ... GOOD LUCK LONGS

[goupupup]

According to the ST moving average the 30-60 days and this is the Yahoo Chart Service, which has turned positive with the closing price today .... This is taking out the previous high of $1.36 few weeks ago. The stock price is higher than two the MA's mentioned and the current trend in place which points to a 30-day MA, up through the 60-day MA, in a week to ten days' time. This will not go unnoticed among technicians and avid stock watchers .... GOOD LUCK LONGS

[goupupup]

Athersys Inc $ 1.21
ATHX 0.09
Short Squeeze Ranking™ view
Daily Short Sale Volume view
Short Interest Ratio (Days To Cover) 0.6
Short Percent of Float 2.41 %
Short % Increase / Decrease -27 %
Short Interest (Current Shares Short) 389,600
Shares Float 16,150,000
Short Interest (Prior Shares Short) 533,300
% From 52-Wk High ($ 3.39) -64.31%
% From 50-Day MA ($ 0.92) 31.04%
% From 200-Day MA ($ 0.87) 38.31%
% From 52-Wk Low ($ 0.13) 830.77%
52-Week Performance 45.78%
Trading Volume - Today vs Avg 45.74%
Trading Volume - Today 307,866
Trading Volume - Average 673,100
Market Cap. 268,728,900
% Owned by Insiders 7.39%
% Owned by Institutions 22.20%
Exchange NAS
Record Date 2023-JanA

[Ecomike]

I prefer long term squeezes of shorts. Milk em for all their worth LOL

$ATHX

[Ecomike]

The wood pecking days here on $ATHX are over now.


Athersys Appoints Joseph Nolan to Its Board of Directors
January 05 2023 - 04:33PM
Business Wire
Alert
Print
Share On Facebook

Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today the appointment of Joseph “Joe” Nolan to its Board of Directors, effective January 4, 2023. Mr. Nolan is an experienced biotechnology and pharmaceutical executive who currently serves as Chief Executive Officer of Jaguar Gene Therapy, LLC. With this appointment, Athersys has five Directors, four of whom are independent.

“Joe is a strong addition to our Board, bringing more than 30 years of experience managing high-value global pipelines, launching multiple successful drugs and optimizing large-scale commercial operations. His understanding of the equity capital markets and his innovative approach to market access supported the successful launches of several drugs including Zolgensma®, a gene therapy product developed by a company that was acquired by Novartis for $8.7 billion,” stated Ismail Kola, Ph.D., Chairman of the Athersys Board of Directors.

“I’m delighted to welcome Joe to the Athersys Board. His experience in building high-performance teams, driving operational efficiencies and launching biopharmaceutical products in competitive markets complement Athersys’ strategy. We look forward to drawing upon his expertise as we advance our corporate strategy and the clinical development of MultiStem®,” stated Dan Camardo, Chief Executive Officer of Athersys.

Mr. Nolan has particular expertise in launching products that treat central nervous system disorders, most in orphan and specialty settings. Prior to Jaguar, he was General Manager of AveXis (now Novartis Gene Therapies), where he was a part of the team that launched Zolgensma for the treatment of spinal muscular atrophy, one of two recently approved gene therapies in the U.S. Earlier in his career, Mr. Nolan served as President at Dohmen Life Science Services, Chief Commercial Officer at Marathon Pharmaceuticals and Chief Commercial Officer at Lundbeck Inc. He has also held senior positions at Takeda Pharmaceuticals and Abbott Laboratories.

“I’m proud to join the Athersys Board and am enthusiastic about MultiStem’s potential across a range of unmet medical needs. My passion is in empowering teams to enhance the quality of care for patients, and in MultiStem I see a global opportunity that I look forward to helping maximize,” stated Mr. Nolan.

Mr. Nolan is a Director of Jaguar Gene Therapy and Axovia Therapeutics. He holds a B.S. in Finance from Tulane University and an MBA from the University of Notre Dame.

[XWAVXALMIMAN]

Nice jump today. Up 20+% and doubled in 1 month.
Somebody knows something

[goupupup]

Get ready for a bidding war!!! Ask yourself who wouldn’t be interested in a Phase 3 for stroke that is OVER 50% enrolled .... The NEW guy Joe Nolan was brought on which may know some INTERESTED players… Dan has a plan regarding a partnership which he kind of mention's it in his last sentence in today's PR paragraph. Mitsubishi reflects growing interest along with LARGER companies in the likes of (PLURAL) in MultiStem. Dan also commenting on an announcement last month made by Healios, Dan was encouraged by Healios’ recent letter of intent to establish a NEW company for the joint development of MultiStem for acute respiratory distress syndrome, or ARDS, with investment from Mitsubishi UFJ Capital which he believes their partnership will continue momentum in clinical development with ALOT of growing interest.... GOOD LUCK LONGS

[goupupup]

https://finance.yahoo.com/news/athersys-provides-multistem-clinical-133000621.html

Stop and think about the market cap regarding Healios it's ONLY been 3 or 4 times that of Athersys. The current market cap of Healios is $120M, and Athersys is only $15M ... Do the math especially when Athersys gets a partnership deal it should have been at $38-$48 million instead and NOT 15M if NOT for the current financial crisis. The company is facing delisting unless they get their share price above 2 and their market cap above 34M which they would also ask for an extension. The odds that happening is second to none with a partner ... Let's NOT forget that Dan has stated that there will be a partnership deal coming sometime soon. I say NO LATER by the end of March which WILL provide PLENTY of funding going forward for M2 results Etc. .... GOOD LUCK LONGS

[Docstemcell2020]

Don't forget kids buy high sell low! ??????

[XWAVXALMIMAN]

4 more days like today and we will be over $1.00 and no delisting.
Tax loss selling is over. Time for some good news and a short squeeze

[Docstemcell2020]

Will they file for bankruptcy on the day they get Delisted???

[goupupup]

https://finance.yahoo.com/news/athersys-inc-nasdaq-athx-q3-145937522.html

[goupupup]

Athersys to present at Advanced Therapies Week, January 17-20 2023, Miami Florida
News
Day 1 - 18 Jan 2023: What Does A Global Supply Chain Look Like for CGT? Defining End-To-End Logistics

11:05am Presentation: The Last Mile to the Patient in Cell Therapy

The supply chain for cell and gene therapy will need to mature and scale significantly to meet the potential commercialization pipeline of the therapies in development today

While all areas of the end to end supply chain have room for improvement, the last mile to the patient is particularly challenged, due to the unique needs in ultracold logistics and limited capacity at clinical sites.

In this presentation, we will summarize the challenges and present new models and technologies that we have explored and developed to support the last mile to the patient for larger-scale allogeneic cell therapies. These ideas should also be relevant for autologous therapies and other players in the cryo logistics space.

Maia Hansen, Chief Operating Officer, Athersys

https://advancedtherapiesweek.phacilitate.com/stream/what-does-a-global-supply-chain-look-like-for-cgt-defining-end-to-end-logistics

[longtrailer]

Healios and Mitsubishi UFJ Capital Enter into a Letter of Intent for Joint Development for HLCM051 (MultiStem) for ARDS (12/14/22) - https://ssl4.eir-parts.net/doc/4593/tdnet/2215163/00.pdf

[BarbaraWalters]

Anybody with me?? Revisited the chart and was wrong about $12PT. Will get $6 though

[longtrailer]

From Stocktwits
Ern_Finkel
$MKGP LaPrade. Also, CEO of USR Drilling with horizontal drilling tech. Big things coming!
Nice tweet!
twitter.com/mavmkgp/status/...

MaverickEnergyGroupLTD@mavmkgp
"Having acquired the 3rd largest oil field in Colorado, $MKGP has begun the planning process for further redevelopment of the Adena Field with our technical advisory board," stated David LaPrade, Chief Operations Officer. #oilandgas
12:13 PM · Dec 8, 2022

[BarbaraWalters]

R/S+Offering are over. $12 PT from here

[goupupup]

New filing which Dan bought 100,000 shares ... GOOD LUCK LONGS

https://www.athersys.com/investors/financial-information/sec-filings/sec-filings-details/default.aspx?FilingId=16218393

[goupupup]

The rising GLOBAL burden of STROKE a Professor Valery Feigin from New Zealand was interviewed at the recent World Stroke Congress in Singapore emphasizes the importance of stroke prevention. His OWN words explained the increasing severity of stroke challenges worldwide. He mentioned in the last 30-40 years, there has been an unprecedented growth in stroke burden and stroke has tripled in the past few decades, with the highest burden in lower-income and lower-middle-income countries.

This is ALREADY a BIG concern If NOT addressed, which it will keep on increasing as time goes on resulting in an unmanageable strain on global health services ... GOOD LUCK LONGS

[jerrybrockman]

Worthless comment

[goupupup]

Preview to the ATHX conference, they will be posting a $2.00 per share loss which is a little less thought ... Also, Helios is claiming ATHX has broken agreement for assistance and supplies, which I'm guessing regarding Multistem. ATHX is protesting and negotiating with a contract manufacturer, hopefully to be successful and work out a deal. Stop and think of the delay in the meeting which might have been to prep the street for the magnitude of the loss, as they have now done. Everyone was thinking the loss per share would have been a BIGGER number, because the rev-split lowered the number of shares and increased the loss per share. This should wake everyone up going forward and the short interest has also dropped ... GOOD LUCK LONGS

http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221111:nBwbbStvPa

[BooDog]

Stuck to the $1.10. Nice. And JUST maybe with the reorg they've done we'll see the follow thru.



Athersys, Inc. Announces Closing of $5.5 Million Confidentially Marketed Public Offering
.
Source: Business Wire

Athersys, Inc. (Nasdaq: ATHX) today announced the closing of its previously announced confidentially marketed public offering with healthcare-focused U.S. institutional investors for the purchase of 5,004,545 shares of the Company’s common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 10,009,090 of common stock at a combined purchase price of $1.10, resulting in gross proceeds of approximately $5.5 million before deducting placement agent fees and other offering expenses. The warrants have an exercise price of $1.10 per share, are exercisable immediately following the date of issuance and will expire five years from the date of issuance.

The Company intends to use the net proceeds from the offering for general corporate purposes.

A.G.P./Alliance Global Partners acted as sole placement agent for the offering.

This offering of the common stock, common stock equivalents and warrants is being made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-235945) previously filed with the U.S. Securities and Exchange Commission (the “SEC”). A final prospectus supplement describing the terms of the proposed offering has been filed with the SEC and is available on the SEC’s website located at http://www.sec.gov. Electronic copies of the prospectus supplement may be obtained, when available, from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at [phone], or by email at [e-mail].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Athersys

Athersys is a biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem® cell therapy product, a patented, adult-derived “off-the-shelf” stem cell product, initially for disease indications in the neurological, inflammatory and immune and other critical care indications and has two ongoing clinical trials evaluating this potential regenerative medicine product. Investors and others should note that we may post information about the Company on our website at www.athersys.com and/or on our accounts on Twitter, Facebook, LinkedIn or other social media platforms. It is possible that the postings could include information deemed to be material information. Therefore, we encourage investors, the media and others interested in the Company to review the information we post on our website at www.athersys.com and on our social media accounts. Follow Athersys on Twitter at www.twitter.com/athersys. Information that we may post about the Company on our website and/or on our accounts on Twitter, Facebook, LinkedIn or other social media platforms may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. You should not place undue reliance on forward-looking statements contained on our website and/or on our accounts on Twitter, Facebook, LinkedIn or other social media platforms, and we undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise.

?

View source version on businesswire.com: https://www.businesswire.com/news/home/20221110006074/en/

Athersys
Ellen Gurley
Manager of Corporate Communications and Investor Relations
[e-mail]

LHA Investor Relations
Tirth T. Patel
212-201-6614
[e-mail]

[BooDog]

Squeeze this puppy already!!

[Docstemcell2020]

Woow

[BooDog]

Maybe they found a solid buyer for the offering.

https://finance.yahoo.com/news/athersys-reschedules-third-quarter-conference-135500220.html

ATHX
-56.45%
Thu, November 10, 2022 at 5:55 AM·2 min read

In this article:

ATHX
-56.45%

CLEVELAND, November 10, 2022--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today that it intends to file its quarterly report on Form 10-Q for the three months ended September 30, 2022 with the U.S. Securities and Exchange Commission (SEC) after market close on Monday, November 14, 2022, issue a news release reporting those financial results and recent business highlights before market open on Tuesday, November 15, 2022, and hold a conference call at 11:00 a.m. Eastern Time on Tuesday, November 15, 2022.

The company is rescheduling the reporting of its third quarter 2022 financial results in order to provide sufficient time to complete the Form 10-Q specifically regarding the accounting for recently issued equity warrants.

Details of the rescheduled conference call are as follows:

Date

November 15, 2022

Time

11:00 a.m. (Eastern Time)

Live webcast registration

Webcast link

Phone registration

Call registration link

Shareholders are encouraged to register and listen to the call using the webcast link above. Once registered, you will receive an email containing the toll-free number, a direct entry passcode and a registrant ID. Please send questions you would like management to address in advance of the call to [e-mail]. If you have already registered for this call, your registration will automatically roll over to the new date and time.

[XWAVXALMIMAN]

We added 45% more shares and the stock goes down over 75%.
We did add some cash to stay in business until we make money. It doesn’t make sense. We better have good news soon or another reverse split is coming. Earnings and conference call tomorrow after close

[BooDog]

Get just 1 thing right!! Kaboom! Fry shorty! MOASS!!! Mother of all short squeeze, MOASS lol usually see this on pinks.
This bio needs to get something right. That simple.

[RagingStocks]

2 Gap downs from the 2's. Sorry for those at the top of this. On watch!

[RagingStocks]

2 Gap downs from the 2's. Sorry for those at the top of this. On watch!

[bigbux1]

In @.54 bounce baby...

[BooDog]

Yeah, squeezing down. Taking nibbles though.

Day's High
0.759
Day's Low
0.5926

[BooDog]

Intraday short squeeze setting up. .629.

[BooDog]

Shs Float 11.74M This is shorts triggering every single stop loss there is on this. PURE manipulation. Crazy how this kind of crap continues.




The dilution picks up once the offering closes. Offering at 1.10

Athersys, Inc. (Nasdaq: ATHX) ("Athersys" or the "Company") today announced the pricing of its previously announced "best efforts" public offering of 5,004,545 shares of common stock (or common stock equivalents) and warrants to purchase 10,009,090 shares of common stock at a combined price of $1.10 per share and accompanying warrant for aggregate gross proceeds of approximately $5.5 million, before deducting placement agent fees and other offering expenses. The warrants will have an exercise price of $1.10 per share, will be exercisable immediately following the date of issuance and will expire five years from the date of issuance.

[willlbone]

Dilution

[Docstemcell2020]

Wow

[goupupup]

https://www.reddit.com/r/ATHX/comments/ykcolv/daniel_camardo_thanks_for_taking_on_athersys/?%24deep_link=true&correlation_id=f7db37f7-d3f8-4df2-a7f8-45dbddaeb993&post_fullname=t3_ykcolv&post_index=1&ref=email_digest&ref_campaign=email_digest&ref_source=email&utm_content=post_title&%243p=e_as&_branch_match_id=829669447967134701&utm_medium=Email%20Amazon%20SES&_branch_referrer=H4sIAAAAAAAAA22QwU7DMBBEvybc2oi4EIpUoUoI8QEcuK022XVixbEte0Po37Oh9IZky6M3Hu%2FIo0gqz3WdmcjJHlPaexem2qSXqjmYdGLAcqcyZje4gB6W7E%2FjlqrMuWredK3ruv%2FL93FWkHWfP94%2F9VAwc5Ci8jL10X%2BpIAyOPfQ4Y6YIMmKYCtiYQXByYYAYAGXkXC5brjI65EDMCbZqlXmVvHDVPPYxZ%2FYoTu87Um5b6kxr2x0Z%2B7Q7kG122G7qgToi5O54NJpLsQjYxfuAM2%2FPGbh1u3ouEH%2Brca8gs1XFMzoP5AYucoVb%2FYRuCP%2B7JS6555uncJEZ%2BhhEP0Pp7xhx4vkH8C5yHIEBAAA%3D

[goupupup]

Dan MUST have a deal in hand and is planning for the future ...According to the Cooperation Agreement from Feb. 2021, Healios can own up to 9.9% of Athersys shares. See the Comprehensive Framework Agreement from Aug. 2021:

https://www.sec.gov/Archives/edgar/data/1368148/000134100421000268/sc13d-a10.htm

The Framework Agreement also states that "Healios retains the right to appoint one nominee for election to the Issuer’s Board of Directors if Healios beneficially owns 5% or more of the Issuer’s outstanding shares of Common Stock. Dr. Kagimoto, Chairman and Chief Executive Officer of Healios, currently serves on the Issuer’s Board of Directors as the Healios designee." Healios ownership either went beneath the 5% threshold or will get there soon. According to the March 2018 agreement:

"during such time as Healios beneficially owns less than 15.0% but 5.0% or more of the Company’s outstanding common stock, the Board will nominate one of Healios’ nominees suitable to the Company to become a member of the Board at each annual election of directors."

https://www.sec.gov/Archives/edgar/data/1368148/000119312518085897/d551745d8k.htm

Healios owned 16,310,526 shares pre-RS which should be 652,421 post-RS.

The number of the outstanding shares is currently close to 13 million.

This is ALLLLLLLLL speculation IF and when Healios has the right to select a board member regarding Traub ... Which is NO GREAT LOSS ... GOOD LUCK LONGS

[goupupup]

https://www.reddit.com/r/ATHX/comments/yitzji/world_stroke_day_talks_about_stem_cell/?%24deep_link=true&correlation_id=652767df-a227-4f05-950a-95bf736b03c5&post_fullname=t3_yitzji&post_index=1&ref=email_digest&ref_campaign=email_digest&ref_source=email&utm_content=post_title&%243p=e_as&_branch_match_id=829669447967134701&utm_medium=Email%20Amazon%20SES&_branch_referrer=H4sIAAAAAAAAA22Q3U7DMAyFn6bcbS3N2gqkCU1CiAfggjvLa9zOa5pEiasxnh6XsTuk%2FBx9J8dxchKJ%2BbksE1nLssUYt479VJr4UtQ7E%2FcEmB9UhsQje3SwJLc%2FranCHIr6Tcflctn%2B5fswK0g6Dx%2Fvn7opmMlLVnll%2BT7zej4kZyFLChOBxSsIuikDHsMiimmGnpxbaxstv7NEEdamCvMqaaGibvuQEjkUDh7YKm%2Bbums7O2ywrrvNbqiazVNToS7HoTPtsTJ9o7kYssCwOOdxprWcgXtXN4%2B9pS81HhUkGlTRjOzA8khZbhB6nCPy6P93c1hST3dP4SL6oOBFv0Hp7zXC4ugHs4AW2nsBAAA%3D

[goupupup]

Dr. Osanai - Multistem Stroke Therapy 40th Annual Meeting of the Japanese Society of Neurotherapy to be held from November 2nd to 4th, 2022 ... GOOD LUCK LONGS

https://www.reddit.com/r/ATHX/comments/yhxj01/dr_osanai_multistem_stroke_therapy/?%24deep_link=true&correlation_id=1a7806bf-1623-4115-8d85-d6e0e22f1524&post_fullname=t3_yhxj01&post_index=1&ref=email_digest&ref_campaign=email_digest&ref_source=email&utm_content=post_title&%243p=e_as&_branch_match_id=829669447967134701&utm_medium=Email%20Amazon%20SES&_branch_referrer=H4sIAAAAAAAAA22QzWrDMBCEn8a9OYkl2w2FUAKl9AF66G1RrXW8if6Q1jh5%2B66b5laQ0PANM7toYk7lZbvNaC3xxqS0cRQuW51eK9XqdEAw5UlkzHSiYBzM2R2mNVXpY6Xe5SzLsvnLD9ELyHKPnx9f8gjwGLiIvE3X864RYTPEYoIh8LNjKoweCud4QeAJs0m3tVdLdWsRE6wLVfqN84yV6oeYMzrDFAOQFd6Y5%2F2u%2Fx7rple6bpumq%2Fd239W2xx0qNTadaiWXYmEYZ%2BeC8bjWaXhsdPcoWLyufQIyjqLQG3Jg6YSF7xAG45OhU%2FjfLXHOAz48gTN7GGJg%2BQKhv2OY2OEPvMOjdXcBAAA%3D

[goupupup]

Dr. Hardy Kagimoto on Treasure Results ... GOOD LUCK LONGS

https://www.reddit.com/r/ATHX/comments/yf9j28/dr_hardy_kagimoto_on_treasure_results/?%24deep_link=true&correlation_id=1e370107-eb40-4449-97ea-47b2f1fa2f14&post_fullname=t3_yf9j28&post_index=1&ref=email_digest&ref_campaign=email_digest&ref_source=email&utm_content=post_title&%243p=e_as&_branch_match_id=829669447967134701&utm_medium=Email%20Amazon%20SES&_branch_referrer=H4sIAAAAAAAAA22Qy2rDMBBFv8bdOQ9L1E0hlEAp%2FYAuuhMTa2wr0YvRiDR%2F33HS7Ap6XM7lXg2amXN5Xa8JrXW8gpxX3sXzWuW3ptMq79FAeRKZyE0ugjeV%2FH5eUo06NN2HrMvlsvrLDykIINmHr89vuQQEjFxEXsfdqXsRYcnMQPZqzjC5kDiZFA0TQqmEhrBUfws0Stq1RcxmmalR70wVm%2B55SETogZ3knBW%2BRdVvtpu%2BxaPetFrrXbvrEVrdH7txO4IcWnI5FTZj9T5CwKVOmcdQd89Fiz9LnwDCURQGcN5YN2HhOzQDhAxuiv%2B7JVUa8OEJrBzMkCLLLwi9PcOOPf4C%2BL4w%2FHoBAAA%3D

[goupupup]

https://www.reddit.com/r/ATHX/comments/ydufqm/treasure_results_presented_at_wsc_2022/?%24deep_link=true&correlation_id=fdc56eb0-d8d8-4b93-b238-a42f8c89d25d&post_fullname=t3_ydufqm&post_index=1&ref=email_digest&ref_campaign=email_digest&ref_source=email&utm_content=post_title&%243p=e_as&_branch_match_id=829669447967134701&utm_medium=Email%20Amazon%20SES&_branch_referrer=H4sIAAAAAAAAA22PwW7DIBBEv8a9OUnBiZxKURWpqvoBPfS2wuzaQcFAYZHbv%2B%2B6aW6VQIzeMMNyYU7labvNhOh4Y1LaeBeuW52eG9XpdCIw5UFkzG5ywXio2Z8ua6rR50a9ylqWZfOXt3EWkGWf398%2B5BAwU%2BAi8hvr%2BLnanMmUmgkyleq5QBIhlwjBMCzFgtoptXZrqe%2BQKME6VKNfOFdq1MHGnMkbdjGAQ%2BEj2v2Bhl2LPfZtNxx1Oyjdt6ZTY2%2F7I6o9Si7FwjBW74OZaa3TcJ%2Fq5rmA9CXGo4BMoyiajfOAbqLCNwjWzMm4KfzvllizpbsnsPIMNsr3Agv9fYYde%2FoBy7fLoHsBAAA%3D

[goupupup]

https://worldstrokecongress.org/register/ ... GOOD LUCK LONGS

[goupupup]

https://www.reddit.com/r/ATHX/comments/y7jpsq/14th_world_stroke_congress_october_2629/?%24deep_link=true&correlation_id=b0e1be33-3ceb-4788-96de-a5b69d6e6193&post_fullname=t3_y7jpsq&post_index=1&ref=email_digest&ref_campaign=email_digest&ref_source=email&utm_content=post_title&%243p=e_as&_branch_match_id=829669447967134701&utm_medium=Email%20Amazon%20SES&_branch_referrer=H4sIAAAAAAAAA22QwU7DMBBEvybckpI4pA1ShSohxAdw4LZy7G1i6thmvVHg79lQekOy5dEbzXjtiTnlx92O0FrHlU6p8i5cdio9FU2r0hFB5zuRkdzogvawkD9OW6pQp6J5kbWua%2FWXN3EWQLJPb6%2FvcgiYMXAW%2Bb3%2FSPlTRN3yBGskbyEzxQuCiWEkzBmi4TggQdM1%2FVaupL%2B1iAm2qQr1zLRg0XQmEqHX7GIAZ4UP91gPqFSpDA5luz8cyr6zWOqHoetth13dK8mlmBnOi%2FdBz7jVKbiNdfVcsPglRi2A8CwKZ%2B08WDdi5isEo%2Bek3Rj%2Bd3NcyODNE7jwvL2Q5R%2BE%2Fl7Djj3%2BADqlkuZ8AQAA

[goupupup]

This posting was added just hours ago and already has 23 applicants which is getting ALOT of TRACTION for a small company. Chief Medical Officer Chief Financial Officer

The new CFO will most likely replace the interim CFO (Kasey Rosado) and will cost less. As for the CMO - Dr. Eric Jenkins is supposed to be Vice President Clinical Development and Medical Affairs at Athersys but his name was removed from the Management Team page a month ago so maybe he is leaving too .... GOOD LUCK LONGS

https://www.linkedin.com/jobs/view/3310960779/?refId=qKJvIWTR5UZgzLOm1YLNDw%3D%3D&trk=d_flagship3_company

https://www.linkedin.com/jobs/view/3310963081/?refId=qKJvIWTR5UZgzLOm1YLNDw%3D%3D&trk=d_flagship3_company

[goupupup]

GOOD THINGS RRRRRRRRRRRR HAPPENING ... GOOD LUCK LONGS

[goupupup]

THE SHORTIES RRRRRR AT IT AGAIN its increased by 58% from 539,819 to 851,000 ... It WILL add MORE FUEL for the LIFTOFF when OUR time comes ... GOOD LUCK LONGS

https://shortsqueeze.com/?symbol=athx

[goupupup]

Transcript : Athersys, Inc. - Special Call
10/06/2022 | 04:00pm

https://www.marketscreener.com/amp/quote/stock/ATHERSYS-INC-431073/news/Transcript-Athersys-Inc-Special-Call-41945896/

[MoogMan]

New article on ATHX https://seekingalpha.com/article/4544918-athersys-is-big-pharma-sleeping-at-the-wheel

[MoogMan]

New article on ATHX https://seekingalpha.com/article/4544918-athersys-is-big-pharma-sleeping-at-the-wheel

[goupupup]

https://www.reddit.com/r/ATHX/comments/xwdmzo/conference_call_tomorrow_4pm/?%24deep_link=true&correlation_id=9bf01878-16b2-495e-80cf-6026795a841e&post_fullname=t3_xwdmzo&post_index=1&ref=email_digest&ref_campaign=email_digest&ref_source=email&utm_content=post_title&%243p=e_as&_branch_match_id=829669447967134701&utm_medium=Email%20Amazon%20SES&_branch_referrer=H4sIAAAAAAAAA22Py2rDMBBFv0bd%2BSnHsQOhBELoB3TRnVCksSOqF9IYh359x0mzK0jocq7uPG6IMR%2BqKoHWBksZY2mN%2F654fGdtx%2BMRhMxvJEMys%2FHSiiXZ421LMX5i7YXOuq7lX14FRyDRPX1%2BfNFDwIHHTPK%2BavcTHsxPkMArEEpaKzC4kFJYRRe3NONUtNMAUWyjMH7GtABre0W%2FwEo0wQujiY%2FXqW6G%2FVA0%2FbUtunEHxVCrqejrtt%2BPOzl0zZaLIaOYFmu9dLCV4%2BI1y9MzXsOdjIZAgokUOGms0GaGjE9Io7oozez%2Fd3NYkoKXR3BBJ2hRpOWJPtqgQQu%2F1sx8uXEBAAA%3D